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1 Introduction
The issue of causal attribution
Causes and effects are essential concepts in situations where human be-
ings want to intervene on the world. Medicine offers a large variety of such
situations. Although intuitive concepts of cause and effect are widely spread
in scientific circles, precise definitions of these concepts are still highly con-
troversial. See, for example, the discussions between holders of the potential
outcomes and of the Directed Acyclic Graphs (DAG) approaches to causal-
ity (Pearl, 2012). Many fields, including philosophy, artificial intelligence,
epidemiology, economics and others, have contributed a vast literature on
causality. This paper focuses on a statistical approach to causality in a
rather simple situation, but complex enough however for pointing out some
general issues.
From the point of view of causality assessment, the field of clinical trials
is characterized by a high level of complexities: causes produce immediate
and delayed effects, for a given effect causes are often multiple, interacting
and interdependent, and a given cause may produce several effects in a
possibly complex dynamic process. This situation suggests that causality
can not be derived from a sole description of reality but should rather be
based on a (simplified) representation of reality, ı.e. on a model. As taken
here, the general approach to a model is statistical, implying a genuinely
stochastic representation of the world.
The randomized controlled trial
The gold standard for causality attribution, in evidence-based medicine,
is the randomized controlled trial (RCT) comparing a treatment group to
a control group, individuals being randomly allocated to one or the other
group. Its advantage lies in its ability to control to a large extent selection
bias and confounding variables both manifest and latent. Developed for
experimental contexts, the RCT is often ill-suited for observational studies,
due to ethical or practical reasons. It has however inspired Donald Rubin
(Rubin, 1974) to propose his potential outcomes/counterfactual approach to
causation in non-experimental situations, where the outcome of the putative
cause should be compared to that of the latter’s counterfactual. The RCT
is not without problems however (see e.g. Diamond, 2014) and Rubin’s
counterfactual approach is open to criticism (among others Pearl, 2009;
Russo, Wunsch, Mouchart, 2011).
From a causal viewpoint, a major problem of the RCT and its offshoot,
the counterfactual model, is that this approach to causal attribution of-
ten associates the intervention and the outcome without fully spelling-out a
testable mechanism linking both (Thompson, 2011). One needs in addition
what H.-P. Blossfeld (2009) has coined a causation as generative process
approach. In other words, one should characterize the properties of the un-
derlying data generating process, ı.e. the mechanism behind the data. More
generally, one requires understanding and testing the plausible mechanism
and sub-mechanisms generating the data in a specific population of refer-
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ence. This mechanism-based perspective is pursued in the present paper.
A structural modelling approach
The statistical view presented here is based on a structural modelling
approach to causality. In this approach, the causal mechanism and sub-
mechanisms are embedded in a recursive decomposition of the multivariate
distribution, the former being typically represented by a Directed Acyclic
Graph (DAG). Causal attribution is accordingly subordinated to the or-
dering of the variables underlying the recursive decomposition, this decom-
position requiring structural validity. The latter is based on conditions of
congruence with field knowledge and of stability, or invariance, under a
class of interventions and of environmental changes; for background and
detail, see in particular Mouchart, Russo and Wunsch (2010). The global
mechanism, or data generating process, is therefore decomposed into an
ordered sequence of conditional distributions, each one standing for a pu-
tative sub-mechanism. Under a supplementary condition of exogeneity, the
conditioning variables can then be interpreted as causing variables for the
corresponding sub-mechanism; for more information, see Mouchart, Russo
and Wunsch (2009).
Object of this paper
The paper considers causal attribution in the case of a particular model,
namely a Sure Outcome of Random Events (SORE ) model developed in
Bouckaert and Mouchart (2001) for the analysis of data from clinical trials.
A distinctive feature of this model is that it takes into account different
observable effects and for each of these, different possible latent causes. On
the basis of this model, the contribution of the present paper is to spell
out different components of causal attribution and to make explicit the bias
resulting from causal evaluations based on correlations among observable
variables only, compared to causal attributions based on explanatory sub-
mechanisms.
The order of exposition is as follows. The next section briefly recalls the
main features of the SORE model for clinical trials. Section 3 deals with
different components of causal attribution in the SORE model. In particular,
the complexity of dealing with latent causes is stressed. In addition, the
section evaluates the bias when ignoring the underlying causal model. The
approach is illustrated by a numerical example, along with a case study
based on real data. The concluding section discusses causality in clinical
trials and the methodology of causal assessment.
2 A SORE Model for clinical trials
2.1 Basic concepts
In this section, a broad outline of the Sure Outcome of Random Events
(SORE) model for clinical trials is briefly recalled. A more detailed presen-
tation is given in Bouckaert and Mouchart [2001].
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The SORE model is characterized by two main features:
(i) two kinds of observable effects are distinguished:
- an effect of type I, designated as therapeutic or main effect, denoted
Z
- an effect of type II, designated as side- or adverse effect, denoted Y
(ii) for each observable effect, Z and Y , two latent factors are consid-
ered:
- a pharmacological (or explained) factor (respectively λ and ν)
- a residual (or unexplained) factor (respectively θ and µ).
The pharmacological latent factors (λ and ν) refer to the action of the
drug, ı.e. are “explained” by the action of the drug, whereas the residual
latent factors (θ and µ) refer to the action of factors other than the drug
itself. Thus, the so-called “placebo” and “nocebo” effects are viewed, in
this paper, as residual, or “unexplained”, factors acting independently of
the pharmacological action of the drug, respectively θ on Z and µ on Y .
The principle issue addressed in this paper is attributing a specific effect
to a specific factor. The answer is clearly relative to a model. The SORE
model is constructed is such a way that the latent variables actually stand
for different direct (or immediate) causes of each of the observable effects.
At the end of this section, the underlying structure of the model is made
explicit through a recursive decomposition of the joint distribution of vari-
ables, and the causality structure is represented graphically by means of the
corresponding Directed Acyclic Graph (DAG; for the characteristics of the
latter, see for instance Pearl, 2000).
In the SORE model, all the variables, ı.e. latent and manifest, are binary
and therefore may be viewed as coding the occurrence of events at the level
of individuals. There are firstly three observable events, namely :
Group allocation X, with X = 1 for the treatment group receiving the
drug under trial, and X = 0 for the control group receiving a non-active
drug.
Therapeutic effect Z, with Z = 1 for health improvement and Z = 0 for
no health improvement.
Side-effect Y , with Y = 1 for the occurrence of a side-effect and Y = 0
for no side-effect.
Secondly, there are four non-observable events, namely:
Pharmacological action λ on the therapeutic effect Z, with λ = 0 for no
action and λ = 1 for a therapeutic action. This event represents a biological
process, for example the reaction between the molecule of the drug and a
receptor.
Pharmacological action ν on the side effect Y , with ν = 0 for no action
and ν = 1 for action. This is also a molecular process involving a drug-
receptor interaction.
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Residual action θ on the therapeutic effect Z, with θ = 0 for no action
and θ = 1 for action. This factor is unrelated to the presence of the molecule
of the active drug.
Residual action µ on the side effect Y , with µ = 0 for no action and
µ = 1 for action. Again, this effect does not depend upon the presence of
the active drug.
Table 1 summarizes the specifics of the model. Notice that the outcomes
pharmacological residual observed
factor factor outcome
therapeutic effect λ θ Z
side effect ν µ Y
Table 1: Latent Factors and Observed Outcomes
generated by µ and by ν, and respectively by θ and by λ, are identical, in so
far as they cannot be distinguished by observation. Furthermore, the seven
binary variables (X,Y, Z, θ, λ, µ, ν) take their values in a space with 27 =
128 points. A saturated model accordingly would require 128 − 1 = 127
parameters. Further structure and restrictions are therefore required.
2.2 Relationships
The latent events θ, λ, µ, ν are included in the model because they cor-
respond to well-known concepts in pharmacology, determining observable
events in a SORE model framework. More specifically, the therapeutic ef-
fect (Z) results from a pharmacological action, from a residual one, or from
both:
Z = θ + λ− θλ (1)
Similarly for the side effect (Y ):
Y = µ+ ν − µν (2)
Furthermore, the logic of the model implies two other deterministic con-
straints, namely that the pharmacological factor of the therapeutic effect is
not possible unless the drug is administered, ı.e. :
{λ = 1} ⇒ {X = 1} (3)
or, equivalently:
λ = λX (3.bis)
and similarly, for the pharmacological factor of the side-effect, ı.e. :
{ν = 1} ⇒ {X = 1} (4)
or, equivalently:
ν = νX (4.bis)
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This global model starts with 7 binary variables; thus a saturated model
would involve 127 parameters but, as shown in Table 2 of Section 2.4, based
on Bouckaert and Mouchart (2001), the logic of the model implies 108 re-
strictions through (1), (2), (3) and (4). These restrictions leave 127 - 108 =
19 free parameters. However, one has only 3 observable variables, namely
X,Y and Z, identifying at most 23−1 = 7 free parameters. More restrictions
are therefore required.
2.3 Hypotheses
We now introduce a set of conditions of stochastic independence. These
conditions formalize structural properties of the model and are context-
dependent. This paper analyzes in depth causality assessment in the specific
case of examining the effect of a particular drug for the treatment of allergic
rhinitis, through a Randomized Controlled Trial (RCT). The hypotheses to
be proposed are based on the randomness of the sampling design (RCT) and
on the specific medical problems involved. These hypotheses also permit
a medically meaningful parameterization that has been at the basis, in a
bayesian estimation, of a prior specification rooted on the medical literature
(Bouckaert and Mouchart, 2000).
Firstly, it is supposed that the allocation of patients to groups is ran-
domly carried out from a reference population. More specifically, it is first
assumed that the residual factors are independent of the group assignment,
in particular:
θ⊥X (5)
It is also assumed that in each group of patients, pharmacologic and residual
factors are independent, in particular:
θ⊥ λ|X (6)
The two conditions (5) and (6) are jointly equivalent to:
θ⊥ (λ,X) (7)
Next, it is assumed that in each group the pharmacological factor producing
the side-effect occurs independently of the residual factors producing the
therapeutic or the side-effects, and independently of the pharmacological
factor producing the therapeutic effect. This is trivial for the group X = 0
because, as expressed in (3), the pharmacologic factor is possible in the
drug-treated patients only. Thus, the probability of a pharmacological factor
producing the side-effect depends upon the group allocation only:
ν⊥ (µ, θ, λ)|X (8)
Finally, it is also assumed that the probability of the residual factor produc-
ing the side-effects (ı.e. µ) depends only upon the therapeutic effect (Z),
that is health status improvement. Given this, the probability of µ is the
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same for all patients irrespectively of their group allocation and whatever
the cause of the improvement or lack of improvement of their health:
µ⊥ (θ, λ,X)|Z (9)
The dependence on Z is motivated by Bernheim and Vrana (1995) who
consider that the side-effects may depend, among others, upon the specific
pathology of the patient. This happens when the variable on which the
symptom is recorded as a side-effect, is also affected by the disease in the
absence of the drug, in addition to the fact that the drug has a pharmacolog-
ical activity on that symptom. Statistically, Z acts as a sufficient summary
of the conditions prevailing for the generation of the residual factor µ.
2.4 Parameterization
Besides the known randomization parameter for the two treatment groups
(E(X) = Q), five unknown parameters are necessary to characterize the
model. Given the above restrictions and because the variables are all binary,
these parameters are specified as follows:
1. The probability of the action of the residual factor on the therapeutic
effect:
β = E(θ)
2. The probability of the pharmacological factor on the therapeutic effect:
α = E(λ|X = 1).
3. The probability of side-effects by a residual factor in improved patients:
η = E(µ|Z = 1)
4. The probability of side-effects by a residual factor in unimproved patients:
ξ = E(µ|Z = 0)
5. The probability of side-effects by the pharmacological factor:
φ = E(ν|X = 1)
Table 2 summarizes the parameterization of the SORE model, given all the
above assumptions and constraints. Actually, the joint distribution of the 7
variables (X, θ, λ, Z, µ, ν, Y ) is recursively decomposed as follows:
pX,θ,λ,Z,µ,ν,Y = pX pθ|X pλ|θ,X pZ|θ,λ,X pµ|Z,λ,θ,X pν|µ,Z,λ,θ,X pY |ν,µ,Z,λ,θ,X
(10)
The hypotheses of conditional independence along with the identities among
binary variables simplify this recursive decomposition into:
pX,θ,λ,Z,µ,ν,Y = pX pθ pλ|X pν|X pZ|θ,λ pµ|Z pY |ν,µ (11)
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Distribution Structural zeroes Independence Parameters
Restrictions
X 0 0 Q
θ|X 0 1 β
λ|θ,X 2 1 α
Z|λ, θ,X 8 0 -
µ|Z, λ, θ,X 10 4 η, ξ
ν|µ,Z, λ, θ,X 24 7 φ
Y |ν, µ, Z, λ, θ,X 64 0 -
127 108 13 6
Table 2: Parameterization of the SORE model
X ν
λ Z µ Y
θ
-
@
@
@R
@
@
@R
- - -
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Figure 1: The DAG of the SORE model
Decomposition (11), represented by the Directed Acyclic Graph (DAG) of
Figure 1, characterizes the structural model that is the basis of the causal
assessment to be developed.
From a causal point of view, this model identifies 7 sub-mechanisms (one
for each variable), two of which (generating X and θ) are purely exogenous.
Among the observable variables, one sees that there is an indirect path from
X (group allocation) to Y (side-effect) through ν, and indirect path from X
to Z (therapeutic effect) through λ, and a third one from Z to Y through
µ.
3 Causal assessment in the SORE model
This section deals with the assessment of the manifest and latent causes of
the two outcomes, Y and Z, generated by a common observed cause X. Of
particular interest is the evaluation of the bias resulting from ignoring the
underlying structural model. This section also builds a bridge between the
terminology of the SORE model and standard epidemiological concepts.
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3.1 Attribution of the therapeutic effect on Z
3.1.1 Within the SORE model
The therapeutic effect (health improvement) may firstly result from the
pharmacological action of the drug (λ). Thus, the Drug Attributable Ther-
apeutic Effect (DATE) may be defined in the SORE model as follows:
DATE = E(λ|X = 1)− E(λ|X = 0) = α− 0 = α (12)
The improvement may also result from a residual factor (θ). Thus, the
Residual Attributable Therapeutic Effect (RATE) may be defined in the
SORE model as:
RATE = E(θ|X = 1)− E(θ|X = 0) = β − β = 0 (13)
Thus, the SORE model ensures the nullity of RATE, a desirable feature.
Finally, the Manifest Attributable Therapeutic Effect (MATE) is defined in
the SORE model as follows:
MATE = E(Z|X = 1)− E(Z|X = 0)
= (α+ β − αβ)− β
= α(1− β) (14)
3.1.2 Ignoring the SORE model
Ignoring the SORE model (ı.e. the fact that λ is latent) leads to evaluate-
ing DATE by MATE, ı.e. introducing a bias by evaluating a property of
the drug at the clinical level only. The Clinical Bias of Therapeutic Effect
(CBTE) is accordingly defined as follows:
CBTE = MATE −DATE = −αβ (15)
Therefore, ignoring the latent mechanisms systematically implies underesti-
mating DATE in clinical trials. In the absence of a control group, DATE
could be evaluated by E(Z|X = 1) = α + β(1 − α), which is equal to
MATE + β and clearly overestimates DATE unless α = 1 or β = 0.
It is possible to correct MATE by dividing it by the probability of
no therapeutic effect in the control group. The result can be called the
“Attributable Fraction of Therapeutic Effect” (AFTE). Note indeed that:
AFTE = MATE/(1− E(Z|X = 0)) = α(1− β)/(1− β)
= α = DATE (16)
It is interesting to note that the definitions of MATE and AFTE correspond
respectively to Berkson’s index (Berkson 1958) and Sheps’ excess risk or
relative difference (Sheps 1961). A measure of “the relative value of a new
treatment” similar to AFTE is given by Fleiss (1981).
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3.2 Attribution of adverse effects
The analysis of side-effects is somewhat more involved than the analysis of
therapeutic effects.
3.2.1 Within the SORE model
The Drug Attributable Side-Effect (DASE) is defined as follows :
DASE = E(ν|X = 1)− E(ν|X = 0) = φ− 0 = φ (17)
Side-effects may also result from a residual factor (µ). Thus, the Residual
Attributable Side-Effect (RASE) is defined as:
RASE = E(µ|X = 1)− E(µ|X = 0) (18)
Decomposing E(µ|X) with respect to Z, RASE may be written as follows
(for a detailed proof, see Appendix A.1.):
RASE = α(1− β)(η − ξ) (19)
Finally, the Manifest Attributable Side-Effect (MASE) is defined by:
MASE = E(Y |X = 1)− E(Y |X = 0) (20)
As shown in Appendix A.1., one obtains:
MASE = RASE +DASE[(1− ξ) − (α+ β − αβ)(η − ξ)] (21)
3.2.2 Ignoring the SORE model
As before, if one ignores the SORE model, one might use MASE to evaluate
DASE, introducing a Clinical Bias of Side-Effect (CBSE) as follows:
CBSE = MASE−DASE = α(1−β)(1−φ)(η− ξ)−φ[ξ+ (η − ξ)β] (22)
The relation between CBSE and α is linear, the slope of which is given by:
∂CBSE
∂α
= (1− β)(1− φ)(η − ξ) > 0 (23)
Thus, the magnitude of CBSE increases with α and this increase is directly
proportional to :
- the increase of the probability of a residual factor providing side-effects
after improvement of the patient’s status (η − ξ),
- the probability of no placebo effect 1− β,
- the probability of no pharmacological toxic effect of the drug 1− φ.
As done for therapeutic effects, a transformation can be applied to MASE
to obtain DASE. The Attributable Fraction of Side Effects (AFSE) is de-
fined separately for the improved (Z = 1) and unimproved (Z = 0) groups,
namely:
AFSE(Z) =
E(Y |X = 1, Z)− E(Y |X = 0, Z)
1− E(Y |X = 0, Z) (24)
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Averaging over Z, one obtains (details given in Appendix A.1. ):
AFSE = E[AFSE(Z)]
= E(Z)AFSE(Z = 1) + (1− E(Z))AFSE(Z = 0)
= φ = DASE (25)
A correct expression can thus be obtained in the same way as a correct ex-
pression for DATE was obtained in (16).
A particular situation arises when η = ξ = ξ¯ ı.e. µ⊥ Z. In such a
situation, side-effects have only two possible causes: placebo toxicity (η =
ξ) and drug toxicity (φ). In this case, the recursive decomposition (11)
simplifies into:
pX,θ,λ,Z,µ,ν,Y = pX pθ pµ pλ|X pν|X pZ|θ,λ pY |ν,µ (26)
and is represented by the Directed Acyclic Graph (DAG) of Figure 2.
X ν
λ Z Y
θ µ
-
? ?
-
6 6
Figure 2: The DAG of the SORE model under µ⊥ Z
Moreover:
RASE = 0
MASE = φ(1 − ξ¯) = DASE(1 − ξ¯)
= P (ν = 1 | X = 1) P (µ = 0)
CBSE = −ξ¯φ (27)
This particular case is interesting for a better grasp of the logic of this model
and of the role of the association between µ and Z. Finally, if η = ξ = 0,
no side effects are observed in control patients, and all the side-effects are
caused by the drug.
3.3 Numerical illustrations
The following numerical exercise evaluates the order of magnitude of the
different effects defined above. In Table 3, we give the CBSE for φ = ξ =
β = 0.1, α varying from 0.5 to 0.9 and η varying from 0.1 to 0.4. It can
12
η =0.1 η =0.2 η =0.3 η =0.4
α =0.5 -0.01 0.030 0.069 0.109
α=0.6 -0.01 0.038 0.085 0.133
α =0.7 -0.01 0.046 0.101 0.157
α =0.8 -0.01 0.054 0.118 0.181
α =0.9 -0.01 0.062 0.134 0.206
Table 3: Expected clinical bias of side effects (CBSE) for some values of the
parameters α and η and for β = φ = ξ = 0.1
be seen that for α = 0.9 and β = 0.1, which amounts to a (manifest)
improvement rate, ı.e. E(Z | X = 1), of 91% for the drug-treated patients,
the CBSE can be considerable.
Assuming that β = φ = ξ = 0.1, α = 0.9 and η = 0.4, Table 4 is
obtained. Following (16) :
Manifest effects Side effects Therapeutic effects
E(Z|X = 1) = 0.91 MASE = 0.306 MATE = 0.81
E(Z|X = 0) = 0.10 DASE = 0.10 DATE = 0.90
E(Y |X = 1) = 0.436 RASE = 0.243 RATE = 0
E(Y |X = 0) = 0.13 CBSE = 0.206 CBTE = −0.09
Table 4: Numerical example β = φ = ξ = 0.1, α = 0.9 and η = 0.4
AFTE =
E(Z|X = 1) − E(Z|X = 0)
1 − E(Z|X = 0) =
0.91 − 0.10
1 − 0.10
= 0.90 ı.e. DATE
In this example, the new drug achieves an improvement rate of 91% com-
pared to 10% for the non active drug, raising thus some hope for a better
management of the disease. The rate of side-effects, however, is disturbingly
high: 43.6% versus 13% for the non active drug. Before looking for another
drug, one should keep in mind that a part of this 30% difference is actually
linked to the achievement of the therapeutic aim.
A similar reasoning holds for cases with η < ξ (ı.e. the improvement in
health decreases the risk of side-effects). Suppose that β = φ = η = 0.1,
α = 0.9 and ξ = 0.4. Then the estimate for MASE is −0.156 and +0.100
for DASE. Thus, when ignoring the model, the Clinical Bias of Side-Effect
(CBSE) is equal to = -0.256. In such a case, one is tempted to attribute
protective effects to a drug (negative MASE) that actually increases the
probability of side-effects (positive DASE). Another drug with similar cura-
tive properties and less side-effects would clearly be a better choice.
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3.4 A Case Study
The original data of this case study and a discussion of the observable vari-
ables are presented in Bouckaert and Mouchart (2001). In a double-blind
randomized control trial, the drug DR has been compared to a non-active
drug (NAD) for the relief of disease DI. Drugs belonging to the same ther-
apeutic class as DR often exhibit the typical side-effect SE, so that this
property can be anticipated from DR too. In this study, 312 patients have
been treated by DR and 103 allocated to a control group receiving NAD.
For each patient, an “improvement score” has been obtained. The results
are summarized in Table 5. It can be observed that SE occurs in 41 + 17
Improved (Z = 1) Not Improved (Z = 0) Total
Side No Side Side No Side
Effects Effects Effects Effects
(Y = 1) (Y = 0) (Y = 1) (Y = 0)
NAD (X = 0) 2 45 4 52 103
DR (X = 1) 41 149 17 105 312
Total 43 194 21 157 415
Table 5: Data of the case-study
= 58 patients out of 312 versus 2+4 = 6 patients out of 103 in the control
group. Thus, the estimate of Eˆ(Y |X = 1) is 18.6 % and the estimate of
Eˆ(Y |X = 0) is 5.8%. The estimate of MASE is accordingly 0.186 - 0.058 =
0.128. The estimate of AFSE is 0.135. See Appendix A.2. for details.
Moreover, SE is observed to occur in 2+41 = 43 out of the 2+45+41+149
= 237 improved patients (Eˆ(Y | Z = 1) = 18%) and in 4+17 = 21 out of
the 4+52 + 17+105 = 178 non-improved patients (Eˆ(Y | Z = 0) = 11, 8%),
raising the question of the respective influences of the drug and of the resid-
ual factors. Concerning the therapeutic effects, estimates for α and β are
respectively 0.281 and 0.456. Therefore, ̂MATE = 0.153 and the observed
clinical bias ̂CBTE is −0.128. Again, details of the computations are given
in Appendix A.2.
The above results are summarized in Table 6. Concerning firstly the ther-
Side-effects Therapeutic effects
MASE = 0.128 MATE = 0.153
DASE = 0.135 DATE = 0.281
RASE = - 0.004 RATE = 0
CBSE = - 0.007 CBTE = - 0.128
Table 6: Results of the case-study
apeutic effect of DR, it can be observed that the manifest effect MATE
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substantially underestimates the drug-attributable effect DATE, as esti-
mated by AFTE. The sole use of MATE would considerably bias the esti-
mate of the therapeutic effect due to the drug. Secondly, concerning possible
side-effects, the manifest effect MASE is very close to the drug-attributable
effect DASE as estimated by AFSE. One could conclude that the drug has a
(slight) therapeutic effect but that its side-effects can not be neglected, the
residual effect RASE being quite small.
4 Conclusions
On causality in clinical trials
Adverse events, or side-effects, will continue to be a source of concerns in the
analysis of the results of clinical trials. In this study, a particular aspect of
the problem has been investigated, ı.e. the distinction between side-effects
directly attributable to the drug (DASE) and side-effects attributable to a
residual, or not drug-related, factor (RASE). It is well-established conven-
tional wisdom that drug-treated patients are usually more likely to exhibit
side-effects than placebo-treated patients (ı.e. MASE is positive). The reg-
ular occurrence of specific adverse reactions to some drugs can even be a
problem for blindness maintenance throughout a trial.
The SORE model has been shown, in this case study, to be flexible
enough to handle this class of issues. This model, crude as it is, can neverthe-
less settle some problems related to the attribution of adverse events, an issue
of considerable importance since powerful but dangerous drugs are already
widely available or under development and since toxicity is the most usual
limit to therapeutic effectiveness. Moreover, the SORE model, integrating
deterministic outcomes into a probabilistic model, could have applications
in other fields too where latent sub-mechanisms are strongly suspected.
On methods of causal assessment
In this model, causal assessment does not result from a sole description of
the data but from a particular class of statistical model, the so-called struc-
tural, or causal, model. The latter is based on a recursive decomposition of
the joint multivariate distribution, representing the global mechanism of the
data-generating process and its sub-mechanisms. For a more comprehensive
presentation, see Mouchart and Russo (2011) and Wunsch, Mouchart and
Russo (2014). In a nutshell, the structural model is based on the current
state of background knowledge and relies on medically meaningful parame-
ters. The structural model should furthermore be invariant under changes
of the environment, e.g. stable from one sample to another.
The recursive decomposition permits the identification of a sequence of
sub-mechanisms composing the global mechanism of the data generating
process. Each sub-mechanism provides a specific causal assessment. In
particular, a cause is viewed as an exogenous variable in a sub-mechanism
(Mouchart, Russo and Wunsch, 2009). The presence of latent variables,
within the global mechanism, impedes the empirical identification of each
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sub-mechanism. It entails causal assessment to aggregate in terms of mani-
fest variables the effect of several sub-mechanisms. The SORE model allows
one to distinguish na¨ıve causal assessment, relying on a prima facie analysis
of the empirical distribution of the manifest variables, from a causal attri-
bution based on a structural model, taking into account both manifest and
latent variables.
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Appendix
A.1. Analytical details
Preliminary steps
E(µ|X = 1) = E(µ|Z = 1, X = 1)E(Z|X = 1) + E(µ|Z = 0, X = 1)[1− E(Z|X = 1)]
= E(µ|Z = 1)E(Z|X = 1) + E(µ|Z = 0)[1− E(Z|X = 1)] because of (9)
= η(α+ β − αβ) + ξ[1− (α+ β − αβ)]
= ξ + (η − ξ)(α+ β − αβ)
E(µ|X = 0) = E(µ|Z = 1, X = 0)E(Z|X = 0) + E(µ|Z = 0, X = 0)[1− E(Z|X = 0)]
= E(µ|Z = 1)E(Z|X = 0) + E(µ|Z = 0)[1− E(Z|X = 0)] because of (9)
= η β + ξ(1 − β)
= ξ + β(η − ξ)
E(Y | X) = E(µ | X) + E(ν | X) − E(µ | X) E(ν | X) from (2) and (8)
= E(ν | X) + E(µ | X)[1 − E(ν | X)]
E(Y | X = 1) = φ + [ξ + (η − ξ)(α+ β − αβ)] (1 − φ)
E(Y | X = 0) = ξ + β(η − ξ) from (4), ı.e. E(ν | X = 0) = 0
Noting that (1) and (8) imply ν⊥ Z | X and ν⊥ µ | Z,X:
E(Y | X,Z) = E(µ | X,Z) + E(ν | X,Z) − E(µ | X,Z) E(ν | X,Z) from (2)
= E(ν | X,Z) + E(µ | X,Z)[1 − E(ν | X,Z)]
= E(ν | X) + E(µ | Z)[1 − E(ν | X)] from (9)
Checking (19): RASE = α(1− β)(η − ξ)
RASE = E(µ|X = 1)− E(µ|X = 0)
= (η − ξ)(α − αβ)
= α(1− β)(η − ξ)
Checking (21): MASE = RASE+DASE[(1− ξ) − (α+ β−αβ)(η− ξ)]
MASE = E(Y |X = 1)− E(Y |X = 0)
= φ + [ξ + (η − ξ)(α+ β − αβ)] (1 − φ) − [ξ + β(η − ξ)]
= (η − ξ)[(α+ β − αβ)(1 − φ) − β] + φ + ξ[1− φ− 1]
= (η − ξ)[(α+ β − αβ)(1 − φ) − β] + φ(1− ξ)
= (η − ξ)α(1− β) − φ(η − ξ)(α+ β − αβ) + φ(1− ξ)
= RASE + DASE[(1− ξ) − (η − ξ)(α+ β − αβ)]
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Checking (25): AFSE = φ
E(Y | X = 1, Z = 1) = φ + η (1 − φ)
E(Y | X = 1, Z = 0) = φ + ξ (1 − φ)
E(Y | X = 0, Z = 1) = η from (4), ı.e. E(ν | X = 0) = 0
E(Y | X = 0, Z = 0) = ξ from (4), ı.e. E(ν | X = 0) = 0
AFSE(Z) =
E(Y |X = 1, Z)− E(Y |X = 0, Z)
1− E(Y |X = 0, Z)
AFSE(Z = 1) =
φ + η (1 − φ) − η
1 − η = φ
AFSE(Z = 0) =
φ + ξ (1 − φ) − ξ
1 − ξ = φ
AFSE = E[AFSE(Z)] = φ
A.2. Numerical results of the Case Study
The numerical illustrations, in Section 3.3, are based on assumedly known
theoretical values of the parameters of a SORE model. The data given in
Table 5 of Section 3.4 are data bearing on real observations. In this Ap-
pendix A.2, estimations of the parameters of a SORE model are obtained
from simple moment estimators. The basic tool is provided by the fact that
the mathematical expectation of a binary variable is equal to the probabil-
ity of being equal to 1 and is accordingly estimated by the sample proportion.
Therapeutic effects
Eˆ(Z | X = 0) = 2 + 45
103
= 0.456 = βˆ because E(Z | X = 0) = β
̂AFTE = Eˆ(Z|X = 1) − Eˆ(Z|X = 0)
1 − Eˆ(Z|X = 0)
=
[(41 + 149)/312] − [(2 + 45)/103]
1 − [(2 + 45)/103]
=
0.609 − 0.456
1 − 0.456 = 0.281 = αˆ
= ̂DATÊMATE = Eˆ(Z|X = 1) − Eˆ(Z|X = 0) = 0.609 − 0.456
= 0.153̂CBTE = ̂MATE − ̂DATE = 0.153 − 0.281 = − 0.128
Side effects
Eˆ(Y | X = 1) = 41 + 17
312
= 0.186
Eˆ(Y | X = 0) = 2 + 4
103
= 0.058
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Eˆ(Y | X = 1, Z = 1) = 41
41 + 149
= 0.216
Eˆ(Y | X = 1, Z = 0) = 17
17 + 105
= 0.139
Eˆ(Y | X = 0, Z = 1) = 2
2 + 45
= 0.043 = ηˆ
Eˆ(Y | X = 0, Z = 0) = 4
4 + 52
= 0.071 = ξˆ
̂AFSE(Z = 1) = Eˆ(Y |X = 1, Z = 1) − Eˆ(Y |X = 0, Z = 1)
1 − Eˆ(Y |X = 0, Z = 1)
=
0.216 − 0.043
1 − 0.043 = 0.181
̂AFSE(Z = 0) = Eˆ(Y |X = 1, Z = 0) − Eˆ(Y |X = 0, Z = 0)
1 − Eˆ(Y |X = 0, Z = 0)
=
0.139 − 0.071
1 − 0.072 = 0.073̂AFSE = Eˆ[ ̂AFSE(Z)]
= (0.181)
43 + 194
415
+ (0.073)
21 + 157
415
= 0.135 = φˆ̂RASE = αˆ (1 − βˆ) (ηˆ − ξˆ)
= (0.281) (1 − 0.456) (0.043 − 0.071)
= − 0.004̂MASE = Eˆ(Y |X = 1)− Eˆ(Y |X = 0) = 0.186 − 0.058
= 0.128̂DASE = φˆ = 0.135̂CBSE = ̂MASE − ̂DASE = 0.128 − 0.135 = − 0.007
Remarks
• As shown in Appendix A.1, ̂AFSE(Z = 1) and ̂AFSE(Z = 0) are two
estimators of φ. At the model level, they have a same value whereas
in the sample these two estimators can have different values and are
averaged to provide a unique estimator of φ.
• No estimator depends upon the value of E(X), ı.e. the proportion of
treated patients and of control patients.
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